The expression of the transmembrane glycoprotein CD38 is well documented in hematological cancers, including multiple myeloma (MM), certain types of lymphoma, and leukemia; the prevalence and expression level of CD38 is lower and more variable in non‐MM cancers.2, 9, 10, 11, 12, 13, 14. This evidence concerns the gene CD38 and hematopoietic and lymphoid cell neoplasm.